Maximus Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.5/10
Best for: coverage in all 50 states, which most of the register will not confirm
Maximus falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
In the price
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Maximus is a men's health platform selling compounded semaglutide from $149.99/mo on a 12-month plan, plus compounded tirzepatide, alongside testosterone replacement therapy and longevity treatments. It covers all 50 states plus DC, and a microdose protocol is available for patients with less weight to lose.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Maximus
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Maximus at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $199.99/mo (NEW: brand-name oral GLP-1; 'Foundayo starting at $199.99 /mo')
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Shipping
- Availability
- All 50 states
- FDA status
- 1 FDA warning letter on record — see below
How Maximus scores
Six columns, each one computed from something Maximus has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10$249.99/month is 32% above the register median of $189 for compounded semaglutide.
Effectiveness25%
10.0/10Dispenses orforglipron and semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
7.5/10On the seller's own pages, a price is published before the questionnaire starts; a live video visit is required, which is slower but is the more careful intake.
Trust & Safety15%
4.5/101 FDA warning letter on record; does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is medium.
Accessibility10%
10.0/10Publishes coverage in 51 of 50 states.
Support10%
4.5/10The price covers medication, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Maximus
Last checked July 2026- Re-read the price on file across 8 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Maximus involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Maximus publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake requires a live video visit with a clinician, which is more than most of the register asks and slower to complete.
- 3Maximus does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, shipping.
- Cheapest standing monthly prices on record: semaglutide $249.99, tirzepatide $359.99. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for all 50 states.
- 1 FDA warning letter on record. The letter itself is linked in the enforcement section below — read what it alleges rather than the fact that it exists.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
GLP-1 medications Maximus offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Peptides Maximus offers
Maximus sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
4-Month plan $199/mo; 12-Month plan $150/mo ('BEST VALUE... Save $100'); homepage teaser 'GLP-1 Starting at $149.99'; /weight-loss hub also shows 'Starting at $116 /28-day supply' (teaser, unreconciled with product page)
4-Month plan $299/mo; 12-Month plan $240/mo; product page 'Personalized doses from $198 /mo' and hub 'Starting at $198 /28-day supply'; homepage teaser 'GLP-1 + GIP Starting at $249.99'
NEW: brand-name oral GLP-1; 'Foundayo starting at $199.99 /mo'
NEW brand-name option
NEW brand-name option
NEW brand-name option
NEW brand-name option; multi-dose KwikPen at same self-pay price as vial
NEW brand-name option; on-label tirzepatide
Check the price yourself before you pay
Every figure here was read off Maximus's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $249.99 a month, within the normal band around this register's $189 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication and shipping
- Coverage is published for all 50 states
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its orforglipron and semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Maximus charges
The standing price at Maximus is $199.99/month, unchanged as the dose goes up. That sits above the middle of the market, which puts the burden on whatever else is in the package. Flat dose pricing matters more than it reads: on a tiered plan the bill grows as the dose does, which means the figure that persuaded you to sign up is not the figure you end up living with.
- Compounded semaglutide — $249.99/month
- Compounded tirzepatide — $359.99/month
- Compounded orforglipron (foundayo) — $199.99/month
- Compounded semaglutide (wegovy) — $249.99/month
- Compounded semaglutide (ozempic) — $349.99/month
- Compounded semaglutide (wegovy) — $349.99/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Breeze Meds dispenses semaglutide and tirzepatide from $199/month, which makes it the honest comparison to run before committing here.
What Maximus dispenses
Maximus prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
What we could verify
On the record: it treats patients in all 50 states. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
- A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.
It fits if
- you want the price to stop moving as your dose climbs
- you need access regardless of where you live
Our read
Maximus costs more than the middle of this market. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.
The Bottom Line
Maximus falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Maximus
Starting at $199.99/month. Check today's price, then book the free consultation.
Where Maximus is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
Maximus has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this Maximus review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Maximus's current pricing
Plans start at $199.99/month. The free consultation is where you learn whether you qualify, and what it costs today.